Acadia Pharmaceuticals Inc. priced an underwritten public offering for gross proceeds of approximately $250 million.
Apellis Pharmaceuticals Inc. closed its private offering of $220 million aggregate principal amount of 3.5% convertible senior notes due 2026.
Boundless Bio Inc. raised $46.4 million in a series A financing.
IGM Biosciences Inc. priced its IPO of 10.93 million shares of its common stock at $16 per share for gross proceeds of approximately $175 million. The shares began trading on Nasdaq under the symbol IGMS.
Linnaeus Therapeutics Inc. said it closed a $12 million series B financing.
Metacrine Inc. has inked a loan and security agreement worth up to $50 million with the private equity-backed health care financier K2 Healthventures.
Mission Bay Capital, an early stage life sciences venture capital firm, closed its third fund at $60 million.
Optinose Inc. entered a note purchase agreement for up to $150 million of senior secured notes with funds managed by Pharmakon Advisors LP, the investment manager of the Biopharma Credit funds.
Provention Bio Inc. priced its public offering grossing the company $40 million.
PTC Therapeutics Inc. priced its private offering of $250 million aggregate principal amount of its convertible senior notes due 2026.
Satsuma Pharmaceuticals Inc. closed its IPO of 5.5 million shares of common stock at $15 each for gross proceeds of approximately $82.5 million. Satsuma’s shares are listed on Nasdaq under the ticker symbol STSA.
Scpharmaceuticals Inc. has established a new restructured four-year $20 million term loan with Solar Capital Ltd. and Silicon Valley Bank.
Springworks Therapeutics Inc. closed its IPO of 10.35 million shares of common stock that includes the exercise in full by the underwriters of their option to purchase up to 1.35 million additional shares at $18 each. The gross proceeds were $186.3 million. The company’s shares are listed on Nasdaq under the ticker symbol SWTX.
Themis Bioscience GmbH closed a €40 million (US$44.3 million) series D round.
Translate Bio Inc. priced its underwritten public offering for aggregate gross proceeds of $90 million.
VBI Vaccines Inc. priced its public offering grossing the company $35 million.
Adaptive Biotechnologies Corp. entered a global agreement with Amgen Inc. for the use of its next-generation sequencing-based Clonoseq assay to assess minimal residual disease across multiple drug development programs within the Amgen hematology portfolio.
Amplyx Pharmaceuticals Inc. executed an exclusive worldwide license agreement with Novartis AG to acquire the rights to the phase II anti-BK virus (BKV) monoclonal antibody, MAU-868, for the treatment and prevention of BKV disease.
Castle Creek Pharmaceutical Holdings will acquire Fibrocell Science Inc., a cell and gene therapy company, for $63.3 million.
Happify Inc. and Sanofi SA are co-developing a digital therapeutic to address key co-morbidities, including depression and anxiety, of patients with multiple sclerosis, which will be based on Happify’s digital platform.
H. Lundbeck A/S is entering the crowded marketplace for antibody-based migraine therapies by acquiring Alder Biopharmaceuticals Inc. for up to $1.95 billion net of cash.
Oncoheroes Biosciences Inc. and Boehringer Ingelheim International GmbH reached an exclusive licensing agreement for volasertib, an investigational cancer compound to treat pediatric cancers.
Y-Trap Inc. signed a collaboration and license agreement with Merck KGaA to exclusively develop antibody-ligand traps for cancer immunotherapy.
Aclaris Therapeutics Inc.’s shares rose on news that A-101, its topical treatment of verruca vulgaris, or common warts, met both the primary and all secondary efficacy endpoints of the phase III THWART-2 trial, the first of two pivotal studies intended to support an NDA filing for the drug, a high-concentration topical hydrogen peroxide solution.
Anabios Corp. said it will receive an FDA grant to further develop its drug discovery platform utilizing cardiomyocytes.
A two-year study concluded that the NIH’s Bethesda, Md., campus needs a $1.3 billion upgrade to its buildings and facilities in order to succeed in what it calls “a highly competitive global biomedical research environment.”
Glaxosmithkline plc has won FDA approval to market Nucala (mepolizumab) for use in children as young as 6 with severe eosinophilic asthma. The therapy already had FDA approval as an add-on maintenance treatment for kids with the same condition ages 12 and older.
Ritter Pharmaceuticals Inc. reported a phase III failure of its lead candidate, RP-G28, designed for patients with lactose intolerance.
Samsung Bioepis Co. Ltd. will expand into the Brazilian market with Brenzys (etanercept), having recently signed a marketing agreement with Brazil’s Ministry of Health.